NGEN — Nervgen Pharma Balance Sheet
0.000.00%
Last trade - 00:00- CA$480.38m
- CA$469.05m
- 18
- 39
- 61
- 32
Annual balance sheet for Nervgen Pharma, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 5.6 | 16.9 | 22.5 | 11.7 | 17.3 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.063 | 0.064 | 0.027 | 0.25 | 0.513 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 6.2 | 17.4 | 23.1 | 12.5 | 19 |
| Net Property, Plant And Equipment | 0.002 | 0.003 | 0.295 | 0.2 | 0 |
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Total Assets | 6.68 | 17.9 | 23.9 | 13.2 | 19.5 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.755 | 1.08 | 10.2 | 15.1 | 16.9 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.755 | 1.08 | 10.4 | 15.2 | 16.9 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 5.92 | 16.8 | 13.5 | -2.01 | 2.58 |
| Total Liabilities & Shareholders' Equity | 6.68 | 17.9 | 23.9 | 13.2 | 19.5 |
| Total Common Shares Outstanding |